Shots:

• The AVT02-GL-302 study evaluates AVT02 in 568 patients at ~30 centers in the EU. Patients were randomized into either of the two arms of the switching module: The first group continues with Humira & the 2nd group is given AVT02 and Humira for an additional 16wks.
• The switching study (AVT02-GL-302) aims to support the approval of AVT02 in the US as an interchangeable biosimilar product with the high concentration (100mg/mL) dosage forms of Humira
• The results showed the bioequivalence of repeated switches b/w Humira & Alvotech’s AVT02- no significant differences were identified in clinical efficacy- safety- or immunogenicity b/w the switching cohort and Humira

  | Ref: Alvotech| Image: Businesswire